Expression of TLR4 and its ligands (HMGB1, heat‐shock protein 90, tenascin C, and fibronectin) is also increased in the skin of SSc patients, highlighting the therapeutic benefit of blocking TLR4. Here, HMGB1 is linked to systemic sclerosis.